Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma : Episode 1

News

Video

October 30, 2023

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Author(s):

Ulka Vaishampayan, MD,Laurence Albiges, MD, PhD

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Now Viewing

EP: 1.Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP: 2.Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP: 3.Imaging and Staging Considerations in Renal Cell Carcinoma

EP: 4.Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP: 5.Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP: 6.Comparing Treatment Combinations in Renal Cell Carcinoma

EP: 7.Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP: 8.Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP: 9.Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

EP: 10.Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP: 11.Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP: 12.Triple Combination Therapies in RCC: Clinical Trial Insights

EP: 13.Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center

January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

December 18th 2024

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC